Kristine B. Patterson

TL;DR: This study demonstrates that the penetration of different human mucosal tissues and their exposure to the pro-drugs TFV and FTC and their active metabolites TFV-DP and FTC-TP is wide ranging and dependent on the tissue type, and reinforces the fact that the success of PrEP will depend on selecting the correct ART that achieves a critical concentration and duration of exposure in vulnerable mucosal tissue.

TL;DR: This randomized trial in antiretroviral-naive patients with HIV-1 showed that a once-daily ritonavir-boosted protease inhibitor re...

TL;DR: Over 2 years, all 3 regimens attained high and equivalent rates of virologic control and tolerability and raltegravir was superior to both protease inhibitors.

TL;DR: This model predicted that ≥98% of the population achieved protective mucosal tissue exposure by the third daily dose of tenofovir disoproxil fumarate plus emtricitabine, and provided a novel approach for future PrEP investigations that can optimize clinical trial dosing strategies.

TL;DR: LPV/r therapy results in modest induction of CYP1A2 and CYP2C9 and potent induction of cytochrome P450 activity and increasing doses of concomitant medications metabolized by these enzymes may be necessary.